Nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, bloating, and reflux appear prominently in current prescribing information for semaglutide and tirzepatide
There is no officially sanctioned dosing schedule for use outside of clinical trials
What Are the Potential Side Effects of This Triple Agonist The most commonly reported adverse effects in clinical studies are gastrointestinal, consistent with the GLP-1 receptor agonist class
"The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION)"
the state Medicaid program is certainly not in a financially stable place
The higher dose frontier: semaglutide 7.2 mg Research continues to explore whether higher semaglutide doses produce faster and greater results